From innovative drug design to clinical success in respiratory tract infections - the first ketolide antimicrobial: 11th European Congress on Clinical Microbiology and Infectious Diseases, Istanbul, Turkey, 2 April 2001FINCH, R; KORTEN, V.The Journal of infection. 2002, Vol 44, issn 0163-4453, 32 p., SUPAConference Proceedings

impact of the fluoroquinolones on gastrointestinal floraKORTEN, V; MURRAY, B. E.Drugs (Basel). 1993, Vol 45, pp 125-133, issn 0012-6667, SUP3Conference Paper

DU-6859a, a new fluoroquinolone agent : comparative in vitro activity against enteric pathogens and multiresistant outpatient Escherichia coliTOMAYKO, J. F; KORTEN, V; MURRAY, B. E et al.Diagnostic microbiology and infectious disease. 1994, Vol 20, Num 1, pp 45-47, issn 0732-8893Conference Paper

Evolving resistance patterns in community-acquired respiratory tract pathogens: First results from the PROTEKT global surveillance studyFELMINGHAM, D.The Journal of infection. 2002, Vol 44, pp 3-10, issn 0163-4453, SUPAConference Paper

Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococciKORTEN, V; ERDEM, I; MURRAY, B. E et al.Diagnostic microbiology and infectious disease. 1996, Vol 26, Num 2, pp 79-85, issn 0732-8893Article

Clinical efficacy of new antibacterial therapies in at-risk populationsLORENZ, J.The Journal of infection. 2002, Vol 44, pp 25-30, issn 0163-4453, SUPAConference Paper

Will resistance to ketolides develop in Streptococcus pneumoniaeLECLERCQ, R.The Journal of infection. 2002, Vol 44, pp 11-16, issn 0163-4453, SUPAConference Paper

Pharmacodynamic rationale for short-duration antibacterial therapyNICOLAU, D. P.The Journal of infection. 2002, Vol 44, pp 17-23, issn 0163-4453, SUPAConference Paper

Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocciKORTEN, V; TOMAYKO, J. F; MURRAY, B. E et al.Antimicrobial agents and chemotherapy. 1994, Vol 38, Num 3, pp 611-615, issn 0066-4804Article

Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalisKORTEN, V; WAI MUN HUANG; MURRAY, B. E et al.Antimicrobial agents and chemotherapy. 1994, Vol 38, Num 9, pp 2091-2094, issn 0066-4804Article

Susceptibility of Bacterial Isolates From Turkey -A Report From the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) ProgramERAKSOY, H; BASUSTAOGLU, A; KORTEN, V et al.Journal of chemotherapy. 2007, Vol 19, Num 6, pp 650-657, issn 1120-009X, 8 p.Article

An unusual native tricuspid valve endocarditis caused by Candida colliculosaKAYGUSUZ, I; MULAZIMOGLU, L; CERIKCIOGLU, N et al.Clinical microbiology and infection. 2003, Vol 9, Num 4, pp 319-322, issn 1198-743X, 4 p.Article

Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infectionMOGULKOC, N; KARAKURT, S; ISALSKA, B et al.American journal of respiratory and critical care medicine. 1999, Vol 160, Num 1, pp 349-353, issn 1073-449XArticle

Reduction of Amphotericin B-Induced Renal Tubular Apoptosis by N-AcetylcysteineODABASI, Z; KARAALP, A; CERMIK, H et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 7, pp 3100-3102, issn 0066-4804, 3 p.Article

Influence of oral glycopeptides on the fecal flora of human volunteers : Selection of highly glycopeptide-resistant enterococciVAN DER AUWERA, P; PENSART, N; KORTEN, V et al.The Journal of infectious diseases. 1996, Vol 173, Num 5, pp 1129-1136, issn 0022-1899Article

Antimicrobial prophylaxis in management of urinary tract stones by extracorporeal shock-wave lithotripsy : is it necessary ?ILKER, Y; TÜRKERI, L. N; KORTEN, V et al.Urology (Ridgewood, NJ). 1995, Vol 46, Num 2, pp 165-167, issn 0090-4295Article

Clinical microbiological case: chronic disseminated candidiasis unresponsive to treatment. Authors' replyRATIP, S; ODABASI, Z; KARTI, S et al.Clinical microbiology and infection. 2002, Vol 8, Num 7, pp 435-436, issn 1198-743X, 5 p.Article

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia : a prospective randomised multicentre trial in patients without previous prophylactic antibioticsAKOVA, M; AKAN, H; KORTEN, V et al.International journal of antimicrobial agents. 1999, Vol 13, Num 1, pp 15-19, issn 0924-8579Article

Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapyCOMETTA, A; KERN, W. V; KORTEN, V et al.Clinical infectious diseases. 2003, Vol 37, Num 3, pp 382-389, issn 1058-4838, 8 p.Article

Treatment of intracranial abscesses : experience with sulbactam/ampicillinAKOVA, M; AKALIN, H. E; KORTEN, V et al.Journal of chemotherapy. 1993, Vol 5, Num 3, pp 181-185, issn 1120-009XArticle